Pharmaceuticals

Hepatocellular Carcinoma Drugs Industry Overview 2025: Growth Projections and Market Trends

November 9, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Are The Current (2025) And Forecast (2029) Sizes Of The Hepatocellular Carcinoma Drugs Market?

The hepatocellular carcinoma drugs market has witnessed substantial growth in recent years. This market is set to expand from $1.16 billion in 2024 to $1.25 billion in 2025, achieving a compound annual growth rate (CAGR) of 7.6%. The historical expansion of this market stems from factors such as an increase in disease incidence, continuous advancements in cancer research, improvements in global healthcare infrastructure, numerous regulatory approvals, and various initiatives promoting awareness and early diagnosis.

The hepatocellular carcinoma drugs market is anticipated to experience robust expansion over the coming years. Its valuation is projected to reach $1.72 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 8.4%. This anticipated growth during the forecast period is primarily driven by advancements in targeted therapies, a rising geriatric demographic, evolving healthcare personalization trends, and the worldwide broadening of treatment availability. Key trends shaping the forecast period encompass improved access to innovative treatments, a focus on patient-centric care, developments in regulatory frameworks, approaches to mitigate drug resistance, and joint research efforts.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10809&type=smp

Which Drivers Are Shaping The Hepatocellular Carcinoma Drugs Industry’s Market Share?

An increasing incidence of hepatocellular carcinoma is anticipated to fuel expansion in the hepatocellular carcinoma drug market in upcoming years. Hepatocellular carcinoma (HCC) is identified as a primary malignant liver condition and represents the most prevalent type of liver cancer, originating in the primary liver cells known as hepatocytes. A majority of HCC cases stem from infections like hepatitis B or C, or from cirrhosis. The ongoing increase in hepatocellular carcinoma cases consequently drives a greater need for efficacious hepatocellular carcinoma drugs to manage the condition. For example, data from 2023, sourced from a report by the American Cancer Society, Inc., a US-based national voluntary health organization committed to eradicating cancer, indicated that new liver cancer diagnoses among females in the United States rose from 12,660 in 2022 to 13,230 in 2023. Consequently, the growing incidence of hepatocellular carcinoma is a key factor propelling the expansion of the hepatocellular carcinoma drug market.

What Are The Different Segment Classifications Within The Hepatocellular Carcinoma Drugs Market?

The hepatocellular carcinoma drugs market covered in this report is segmented –

1) By Type: Brachytherapy, Chemotherapy

2) By Drug Class: PD-1/PD-L1 Inhibitors, Tyrosine Kinase Inhibitors

3) By End User: Hospitals, Clinics, Cancer Rehabilitation Centers, Ambulatory Surgical Centers

Subsegments:

1) By Brachytherapy: Radioactive Seed Implants, Balloon-Activated Brachytherapy, SIRT (Selective Internal Radiation Therapy)

2) By Chemotherapy: Systemic Chemotherapy, Targeted Therapy Agents, Combination Chemotherapy Regimens, Adjuvant Chemotherapy

Which Market Trends Are Creating New Opportunities In The Hepatocellular Carcinoma Drugs Industry?

Companies operating in the hepatocellular carcinoma drugs market are actively developing laboratory-manufactured molecules, such as monoclonal antibodies (mAb), to expand their customer reach, increase sales, and boost revenue. A monoclonal antibody (mAb) is a molecule produced in a laboratory, engineered to replicate the immune system’s natural capacity to combat harmful pathogens like bacteria or viruses. For instance, in October 2022, AstraZeneca PLC, a UK-based pharmaceutical and biotechnology company, announced the US Food and Drug Administration (FDA) approval for Imjudo (tremelimumab) in combination with Imfinzi (durvalumab), indicated for adult patients with hepatocellular carcinoma (HCC). Imfinzi (durvalumab) is a distinct human monoclonal antibody that effectively binds to the PD-L1 protein. This action hinders the interaction between PD-L1 and the PD-1 and CD80 proteins, disrupting the tumor’s ability to evade the immune system and thereby releasing the inhibition of immune responses. As for Imjudo (tremelimumab), it is a human monoclonal antibody specifically designed to target the activity of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Imjudo functions by blocking CTLA-4 activity, which promotes T-cell activation, primes the immune response against cancer, and fosters the death of cancer cells.

Which Major Firms Are Strengthening Their Position In The Hepatocellular Carcinoma Drugs Industry?

Major companies operating in the hepatocellular carcinoma drugs market include AbbVie Inc., Amgen Inc., Bayer AG, Bristol-Myers Squibb Company, Eisai Co.Ltd., Eli Lilly and Company, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd, Gilead Sciences Inc., Exelixis Inc., Ipsen Pharma Biotech SAS, AstraZeneca plc, BeiGene Ltd., Ono Pharmaceutical Co. Ltd., Roche Holdings AG, Sanofi S.A., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Otsuka Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Hengrui Medicine Co. Ltd., CSPC Pharmaceutical Group Limited, Hutchison China MediTech Limited, Jiangsu Hengrui Medicine Co. Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/hepatocellular-carcinoma-drugs-global-market-report

How Is Hepatocellular Carcinoma Drugs Market Demand Varying Across Different Regions?

North America was the largest region in the hepatocellular carcinoma drug market in 2024. The regions covered in the hepatocellular carcinoma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Hepatocellular Carcinoma Drugs Market Report:

https://www.thebusinessresearchcompany.com/customise?id=10809&type=smp

Browse Through More Reports Similar to the Global Hepatocellular Carcinoma Drugs Market 2025, By The Business Research Company

Muscle Relaxant Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/muscle-relaxant-drugs-global-market-report

Alzheimers Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report

Osteoporosis Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/osteoporosis-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795